Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;69(3):1613-1620.
doi: 10.1007/s11686-024-00903-1. Epub 2024 Aug 20.

Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis

Affiliations

Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis

Kübra Kelleci et al. Acta Parasitol. 2024 Sep.

Abstract

Visceral Leishmaniasis is a serious public health problem caused by Leishmania species parasites. Approximately 500 thousand people get Visceral Leishmaniasis (VL) every year. An effective and reliable vaccine against the disease has still not been formulated. Choosing the right adjuvant is important to increase immunogenicity in vaccines prepared with total antigens. In this study, we investigate the ideal adjuvant for use in vaccine formulations against VL. For this purpose, Leishmania antigens (FTLA) obtained from L. infantum parasites by the freeze-thaw method and three different adjuvants (alum-saponin and calcium phosphate) were used. The effectiveness of the formulations was investigated in vitro by cell viability analysis and determination of nitric oxide and cytokine production abilities in J774 macrophage cells. According to the study results, it was determined that formulations prepared with calcium phosphate produced 72% more NO and approximately 7.2 times more IL-12 cytokine. The results obtained showed that calcium phosphate salts can be used as ideal adjuvants in vaccine research against leishmaniasis.

Keywords: Adjuvant; Calcium phosphate; Leishmaniasis; Vaccine.

PubMed Disclaimer

Similar articles

References

    1. Kelleci K, Allahverdiyev A, Bağirova M, Ihlamur M, Abamor EŞ (2023) Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: a review. J Vector Borne Dis 60(2):125–141 - DOI - PubMed
    1. Allahverdiyev A, Bağirova M, Oztel ON, Elçıçek S, Ateş SC, Karaca TD (2010) Approaches and problems in vaccine development against leishmaniasis. Turkiye Parazitolojii Dergisi 34(2):122–130 - PubMed
    1. Kelleci K (2022) Determination of Immunostimulatory Efficacy of Benzimidazole Derivatives Against Leishmania infantum. Sys Rev Pharm 2022; 13(12): 826–830
    1. Kelleci K, Gölebatmaz E (2023) In Vitro determination of Antileshmanial activities of Benzimidazolium derivatives on L. major promastigotes and amastigotes. Acta Parasitol 68(1):51–55 - DOI - PubMed
    1. Severino P, Santana W, Lisboa ES, Santos VLD, Lima ETDS, Cardoso JC, Jain S (2022) Cutaneous/Mucocutaneous Leishmaniasis Treatment for Wound Healing: classical versus New Treatment approaches. Microbiol Res 13(4):836–852 - DOI

MeSH terms

LinkOut - more resources